The Fastest-Ever Medical Linear Accelerator Could Revolutionize Cancer Treatment
Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Transforming Cancer Care
Stanford Cancer Initiative is an ambitious program to transform the care experience of every cancer patient treated at Stanford. The Initiative combines the latest research and information management protocols with multi-disciplinary, patient-centered care to improve quality of life and overall health outcomes. Integrating leading-edge research and comprehensive care to dramatically change the prognosis and treatment of cancer.
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford, along with its partner institution, the Cancer Prevention Institute of California. Its nearly 400 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Six groups of researchers, including one from Stanford, collaborated to study the effect of advances in breast cancer screening and treatment on mortality rates.
Stanford scientists have developed a biochemical screen that identifies molecules critical to immunotherapy for a host of diseases, including cancer.
Chemotherapy use for early stage breast cancer declined from 2013 to 2015, possibly due to a preference for less toxic treatments, according to researchers at Stanford and the University of Michigan.